Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 ( MK2 ) pathway in both biochemical ( IC 50 =156.3 nM) and cell based assays ( EC 50 =89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > MAPKAPK2 (MK2)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.